

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/761,167	01/12/2001	Joseph Kevin Gogerty	PO4813USO PHI 1315	4720
27142	7590 10/16/2003		EXAMINER	
MCKEE, VOORHEES & SEASE, P.L.C. ATTN: PIONEER HI-BRED			FOX, DAVID T	
801 GRAND AVENUE, SUITE 3200 DES MOINES, IA 50309-2721			ART UNIT	PAPER NUMBER
			1638	

DATE MAILED: 10/16/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/761,167	GOGERTY, JOSEPH KEVIN			
		Examiner	Art Unit			
		David T. Fox	1638			
Period fo	The MAILING DATE of this communication app r Reply	ears on the cover sheet w	ith the correspondence address			
THE M - Exten after S - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Is slons of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, apply received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a n within the statutory minimum of thir ill apply and will expire SIX (6) MON cause the application to become At	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
1)⊠	Responsive to communication(s) filed on 30 J	<u>uly 2003</u> .				
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.				
3)	Since this application is in condition for allowa closed in accordance with the practice under the					
· · _	on of Claims					
4)⊠ Claim(s) <u>1-8,20,33-43,45,46,49-52 and 55</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
· · · · · · · · · · · · · · · · · · ·	Claim(s) <u>1-7,20,41-43,45 and 46</u> is/are allowed					
	Claim(s) <u>8,33-40,49-52 and 55</u> is/are rejected.					
	Claim(s) is/are objected to.					
	Claim(s) are subject to restriction and/or on Papers	election requirement.				
	•					
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
	Acknowledgment is made of a claim for foreign	priority under 35 LLS C	8 119(a)-(d) or (f)			
	☐ All b)☐ Some * c)☐ None of:	priority under 60 0.0.0.	3 110(a) -(a) 01 (i).			
سرب د	1.☐ Certified copies of the priority documents	have been received				
	2.☐ Certified copies of the priority documents		application No			
	3. ☐ Copies of the certified copies of the priori application from the International Bur ee the attached detailed Office action for a list of	ity documents have been eau (PCT Rule 17.2(a)).	received in this National Stage			
	cknowledgment is made of a claim for domestic	•				
a)	☐ The translation of the foreign language procknowledgment is made of a claim for domestic	visional application has b	een received.			
Attachment		s priority under 33 U.S.C.	33 120 and/or 121.			
1) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) eation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of I	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			

Art Unit: 1638

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 30 July 2003 has been entered.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-8, 20,33-43, 45-46, 49-52 and 55 are pending. Applicant's amendments and arguments of 30 July 2003 have overcome the outstanding indefiniteness rejection except as indicated below, the new matter rejection, and the enablement rejection regarding a deposit of the parent lines.

Claim 8 remains rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, as stated on page 2 of the last Office action.

Claims 52 (amended) and 55 (newly submitted) are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 52 is indefinite in its dependence upon non-existent claim 62. It appears that the claim was intended to depend upon claim 51.

Claim 55 is indefinite in its recitation of "no statisitically significant variation from 35Y54", as it is unclear whether the variation is being measured on the basis of the

Art Unit: 1638

expression of individual genes, the expression of particular traits, or the presence one or more traits.

Claims 8, 33-40, 49-52 and 55 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, as stated on page 5 of the last Office action for claims 8, 33-35, 37-40, 44 and 47-54.

Claims 8, 33-40, 49-52 and 55 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, as stated on page 5 of the last Office action for claims 8, 33-35, 37-40, 44 and 47-54.

The claims remain free of the prior art, as stated on page 5 of the last Office action.

Claims 1-7, 20, 41-43 and 45-46 are allowed.

Applicant's arguments filed 30 July 2003, insofar as they pertain to the rejections above, have been fully considered but they are not persuasive.

Applicant urges that the amendment to claim 8 obviates the outstanding indefiniteness rejection. The Examiner maintains that claim 8 is confusing for chacterizing the male fertile plant of claim 2 as suddenly being male sterile.

Art Unit: 1638

Applicant urges that the claim amendments obviate the written description rejection, in view of the well-known nature of the backcrossing technique. The Examiner notes that claims 33 and 37 recite the broad genera of any gene whose proteinaceous or non-proteinaceous product somehow modifies fatty acid metabolism, starch metabolism, or phytate content. In contrast, the specification only provides guidance for particular individual genes within each of these genera. Unlike the other recited traits whose genera of genes conferring them have been well-characterized in the art, the latter three traits are the results of complex metabolic processes involving a multitude of enzymes, each encoded by a different gene. It is noted that Applicant has amended the claims in accordance with the Examiner's previous suggestions. Upon further review, it has been determined that further refinement of claim language was required in order to satisfy the written description requirement. The confusion is regretted.

Regarding backcrossing, the Examiner maintains that the knowledge of a particular breeding technique does not address the issue of the adequacy under 35 USC 112, first paragraph, of the written description of the plants involved in those techniques or produced by those techniques. While the backcross technique may be employed to introgress a particular gene into a recurrent parent and to obtain a plant which is substantially similar to the original recurrent parent, the specification fails to provide any characterization of the multitude of plants which exhibit some but not all of the collection of traits which render the exemplified hybrid patentable. See also Openshaw et al appended to the amendment of 30 July 2003, who teach that linkage

Art Unit: 1638

drag will interfere with successful introgressing of a desired trait while otherwise preserving the recurrent parent's genotype (page 43, column 1, bottom paragraph), and that at least four generations of crosses are needed to constitute more than 90% of the recurrent parent genome. The instant claims do not recite any number of generations of crosses. Thus, the claims read on plants with much fewer than 90% of the recurrent parent's genome, and with a substantial portion of the genome from a multitude of uncharacterized donor parents.

Applicant urges that the enablement rejection is improper, given the deposit of the hybrid and its parents, and the lack of a requirement to teach what is well known in the art, wherein one skilled in the art could evaluate the various traits of the plant products.

The Examiner maintains that the deposit of the parents or resultant hybrid does not address the enablement of claims drawn to a multitude of plants derived therefrom, produced by crossing with a multitude of undisclosed breeding partners. For transformation claims, the effect of increasing or decreasing the expression of an individual gene in complex metabolic pathways has not been well-characterized either by Applicant or the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David T. Fox whose telephone number is (703) 308-0280. The examiner can normally be reached on Monday through Friday from 10:30AM to 7:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached on (703) 306-3218. The fax phone number for this Group is (703) 872-9306. The after final fax phone number is (703) 872-9307.

October 7, 2003

DAVID T. FOX
PRIMARY EXAMINER
GROUP 480/63 8